上海三友医疗器械股份有限公司关于增设募集资金专项账户并签订募集资金专户存储三方监管协议的公告

Group 1 - The company has approved the use of idle raised funds not exceeding 90 million yuan to temporarily supplement working capital, with a usage period of no more than 12 months from the board's approval date [2][6][7] - The company has established a special account for raised funds, which will only be used for temporarily supplementing working capital, and has signed a tripartite supervision agreement with the sponsor and the bank [3][5][6] - The company raised a total of 1,075,950,160 yuan from its initial public offering, with a net amount of 978,057,381.28 yuan after deducting issuance costs [2][4] Group 2 - The company will have 15,639,463 shares listed for circulation on September 15, 2025, following the issuance of shares to specific investors [15][16] - The total share capital of the company will increase to 277,885,415 shares after the issuance, and further to 333,462,498 shares after a capital reserve transfer [17][18] - The independent financial advisor has confirmed that the shareholders of the restricted shares have complied with their commitments, and the listing of these shares meets regulatory requirements [19][20] Group 3 - The company will participate in a collective performance briefing for the medical device industry on September 17, 2025, to communicate its half-year results and address investor questions [33][34] - Investors can submit questions for the briefing from September 10 to September 16, 2025, and the company will respond to commonly asked questions during the event [35][36]